Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. reports clinical and corporate developments for its T cell receptor-engineered T cell therapy pipeline. The company’s cancer programs include TSC-101 in the ALLOHA heme trial for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, and CD45-targeted candidates TSC-102-A01 and TSC-102-A03 with cleared IND applications.
Recurring TCRX updates cover clinical data presentations, trial enrollment and manufacturing-process updates, FDA interactions, financial results, healthcare conference participation, and portfolio priorities. The company also describes early work in in vivo engineering for solid tumors and target discovery in T cell-mediated autoimmune disorders.
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the FDA's clearance of its investigational new drug (IND) applications for its solid tumor program, T-Plex, along with two TCR-T products targeting MAGE-A1. T-Plex will facilitate customized combinations of TCR-T therapies, enabling personalized treatment based on tumor characteristics. The first two INDs target specific HLA types and are pivotal for advancing TScan's ImmunoBank. The company plans to initiate a multicenter Phase 1 clinical trial for various cancers by mid-2023, with initial results expected by year-end, marking significant progress in tailored cancer therapies.
TScan Therapeutics (TCRX) announced progress in its clinical pipeline, focusing on T cell receptor (TCR)-engineered therapies for cancer. The Phase 1 umbrella trial for treatments TSC-100 and TSC-101 is active across five sites, with expectations to enroll first cohorts in 1H 2023 and interim data due by year-end. The company has filed INDs for multiple TCRs targeting solid tumors and has sufficient cash to fund operations into Q2 2024. Leadership emphasized 2023 as a pivotal year, anticipating significant data readouts.
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the presentation of its Phase 1 trial design for TSC-100 and TSC-101, aimed at treating residual leukemia post-hematopoietic cell transplantation (HCT), at the 64th American Society of Hematology Annual Meeting 2022. The therapies target specific minor histocompatibility antigens and aim to reduce disease relapse. The company plans to enroll the first trial cohorts in H1 2023, with interim data expected by the end of 2023.
Summary not available.
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced participation in the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 10:55 a.m. ET. The management will engage in a virtual fireside chat, which will be available via webcast on the company's website under the "Events and Presentations" section. An archived replay will be accessible for 90 days post-event. TScan is focused on developing T cell receptor-engineered therapies for cancer, targeting residual disease and relapse prevention in patients with hematologic malignancies.
TScan Therapeutics (TCRX) is advancing its T cell receptor-engineered therapies for cancer treatment, focusing on multiplexed TCR-T therapy against solid tumors. The company presented key findings at the SITC Annual Meeting, highlighting the discovery of PRAME-specific TCRs showing strong in vitro and in vivo efficacy. TScan plans to file IND applications for two candidates by the end of 2022 and aims to expand its ImmunoBank for customized therapies. These developments indicate a commitment to addressing tumor heterogeneity and improving treatment outcomes.
TScan Therapeutics (TCRX) announced strong progress in its hematologic malignancies program, with four sites now enrolling patients. The company completed a pre-IND meeting with the FDA for its solid tumor program, indicating a clear path for future IND filings. TScan ended Q3 2022 with $137.3 million in cash, projected to fund operations through Q2 2024. Revenue surged to $3.4 million, up from $2.4 million year-over-year, driven by a collaboration with Novartis. However, TScan reported a net loss of $16.2 million, slightly higher than the previous year.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will host a virtual investor event on November 14, 2022, at 5:00 PM ET. This event will review poster presentations from the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting related to their solid tumor TCR-T candidates. TScan's multiplexed therapy aims to address antigen heterogeneity and HLA loss in cancer treatment. Interested participants can register through the provided link, and a replay will be available on TScan’s website.
TScan Therapeutics, Inc. (TCRX) announced the acceptance of a trial in progress abstract for TSC-100 and TSC-101 at the ASH Annual Meeting scheduled for December 10-13, 2022. The poster presentation, titled 'A Phase 1 Umbrella Study of TCR-Engineered T Cells,' will be presented by Dr. Ran Reshef. TSC-100 and TSC-101 are designed to target HA-1 and HA-2 to prevent relapse in AML, ALL, and MDS patients post-allogeneic transplant. The Phase 1 trial is currently open for enrollment, aiming to improve patient outcomes after reduced-intensity conditioning transplants.
TScan Therapeutics, Inc. (TCRX) announced the acceptance of two abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place from November 8–12, 2022, in Boston, MA. The presentations will cover the development of TCR-T therapies targeting MAGEA1 and PRAME to boost therapeutic efficacy, alongside TSC-203-A02, a candidate for treating solid tumors. The company’s ongoing research aims to enhance TCR-T therapeutic options for cancer patients, focusing on both hematologic malignancies and solid tumors.